31 August 2021
Investor report 1nd half of 2021 R&R Mechatronics International BV
RR Mechatronics (RRM) has clearly performed better in the first half of 2021 than both the budget and compared to the first half of 2020, with it being noted that RRM is still experiencing the consequences of Corona in 2021. For example, pausing clinical trials at pharma companies leads to a delay in the growth of Lorrca sales. RRM has used Corona schemes offered by the government.
We are confronted with disruptions in our purchasing chains caused by the global effects of Corona. For the time being, we are able to carry out our deliveries as planned. In order to best respond to potential supply risks, we have increased the company's financial resources to be able to purchase supplies earlier than would be considered under normal circumstances. To this end, the shareholders strengthened their capital with Euro 2021 in the first half of 1.425.000 and RRM used a Corona bridging loan (COL) from the government of Euro 1.500.000.
The size of the order book had risen to a record high at the end of the first half of the year. Our modernization program of the Starrsed clarifiers is on schedule. The introduction timing is confidential for commercial reasons. The demand for the new RPI, which will be delivered in volume for the first time at the end of this year, is higher than expected in our budget.
Jan Buis
CEO
